Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06663358 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Study acronym: MODERN
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 1 to 10v3
  2. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Oct 2029 to Nov 2029 · Start date changed from estimate of Oct 2024 to Nov 6, 2024v2 Show 2 more changesShow less
    • Primary and study completion dates: Oct 2029 to Nov 2029
    • Start date changed from estimate of Oct 2024 to Nov 6, 2024
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.
Trial Details
NCT Number NCT06663358
Lead Sponsor Chiesi Farmaceutici S.p.A.
Conditions Fabry Disease
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov